A PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NA??VE PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA
Latest Information Update: 10 Feb 2026
At a glance
- Drugs 707 3SBio (Primary) ; Nivolumab (Primary) ; Antineoplastics
- Indications Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
Most Recent Events
- 10 Feb 2026 New trial record